198 related articles for article (PubMed ID: 19028438)
1. Effect of levodopa and entacapone treatment on plasma homocysteine levels in Parkinson's disease patients.
Nevrly M; Kanovsky P; Vranova H; Langova K; Hlustik P
Parkinsonism Relat Disord; 2009 Jul; 15(6):477-8. PubMed ID: 19028438
[No Abstract] [Full Text] [Related]
2. The influence of levodopa, entacapone and homocysteine on prevalence of polyneuropathy in patients with Parkinson's disease.
Grofik M; Sivák Š; Nosáľ V; Turčanová Koprušáková M; Michalik J; Čierny D; Tatarková Z; Kurča E
J Neurol Sci; 2018 Sep; 392():28-31. PubMed ID: 30097148
[No Abstract] [Full Text] [Related]
3. Reduced plasma homocysteine levels in levodopa/entacapone treated Parkinson patients.
Valkovic P; Benetin J; Blazícek P; Valkovicová L; Gmitterová K; Kukumberg P
Parkinsonism Relat Disord; 2005 Jun; 11(4):253-6. PubMed ID: 15878587
[TBL] [Abstract][Full Text] [Related]
4. Effects of vitamin B12, folate, and entacapone on homocysteine levels in levodopa-treated Parkinson's disease patients: A randomized controlled study.
Anamnart C; Kitjarak R
J Clin Neurosci; 2021 Jun; 88():226-231. PubMed ID: 33992189
[TBL] [Abstract][Full Text] [Related]
5. Effect of entacapone on plasma homocysteine levels in Parkinson's disease patients.
Nevrly M; Kanovsky P; Vranova H; Langova K; Hlustik P
Neurol Sci; 2010 Oct; 31(5):565-9. PubMed ID: 20464572
[TBL] [Abstract][Full Text] [Related]
6. Vitamins and entacapone in levodopa-induced hyperhomocysteinemia: a randomized controlled study.
Postuma RB; Espay AJ; Zadikoff C; Suchowersky O; Martin WR; Lafontaine AL; Ranawaya R; Camicioli R; Lang AE
Neurology; 2006 Jun; 66(12):1941-3. PubMed ID: 16801668
[TBL] [Abstract][Full Text] [Related]
7. [Effects of entacapone on plasma homocysteine in Parkinson's disease patients on levodopa].
Zhao P; Yang JF; Liu W; Wang Y; Sun YN; Li Q; Zhang W; Zhang BS
Zhonghua Yi Xue Za Zhi; 2013 Feb; 93(7):512-5. PubMed ID: 23660319
[TBL] [Abstract][Full Text] [Related]
8. Effects of levodopa and COMT inhibitors on plasma homocysteine in Parkinson's disease patients.
Lamberti P; Zoccolella S; Iliceto G; Armenise E; Fraddosio A; de Mari M; Livrea P
Mov Disord; 2005 Jan; 20(1):69-72. PubMed ID: 15390046
[TBL] [Abstract][Full Text] [Related]
9. Relationship between 3-O-methyldopa and the clinical effects of entacapone in advanced Parkinson's disease.
Ishihara A; Miyachi T; Nakamura T; Ohtsuki T; Kimura Y; Kihira K; Yamawaki T; Matsumoto M
Hiroshima J Med Sci; 2011 Sep; 60(3):57-62. PubMed ID: 22053701
[TBL] [Abstract][Full Text] [Related]
10. Quality of life in early Parkinson's disease treated with levodopa/carbidopa/entacapone.
Fung VS; Herawati L; Wan Y; ;
Mov Disord; 2009 Jan; 24(1):25-31. PubMed ID: 18846551
[TBL] [Abstract][Full Text] [Related]
11. Simultaneous MAO-B and COMT inhibition in L-Dopa-treated patients with Parkinson's disease.
Lyytinen J; Kaakkola S; Ahtila S; Tuomainen P; Teräväinen H
Mov Disord; 1997 Jul; 12(4):497-505. PubMed ID: 9251066
[TBL] [Abstract][Full Text] [Related]
12. Bimodal administration of entacapone in Parkinson's disease patients improves motor control.
Bet L; Bareggi SR; Pacei F; Bondiolotti G; Meola G; Schapira AH
Eur J Neurol; 2008 Mar; 15(3):268-73. PubMed ID: 18290846
[TBL] [Abstract][Full Text] [Related]
13. Double-blind, placebo-controlled study of entacapone in levodopa-treated patients with stable Parkinson disease.
Olanow CW; Kieburtz K; Stern M; Watts R; Langston JW; Guarnieri M; Hubble J;
Arch Neurol; 2004 Oct; 61(10):1563-8. PubMed ID: 15477510
[TBL] [Abstract][Full Text] [Related]
14. The COMT Val158Met polymorphism affects the response to entacapone in Parkinson's disease: a randomized crossover clinical trial.
Corvol JC; Bonnet C; Charbonnier-Beaupel F; Bonnet AM; Fiévet MH; Bellanger A; Roze E; Meliksetyan G; Ben Djebara M; Hartmann A; Lacomblez L; Vrignaud C; Zahr N; Agid Y; Costentin J; Hulot JS; Vidailhet M
Ann Neurol; 2011 Jan; 69(1):111-8. PubMed ID: 21280081
[TBL] [Abstract][Full Text] [Related]
15. Treatment of end-of-dose wearing-off in parkinson's disease: stalevo (levodopa/carbidopa/entacapone) and levodopa/DDCI given in combination with Comtess/Comtan (entacapone) provide equivalent improvements in symptom control superior to that of traditional levodopa/DDCI treatment.
Brooks DJ; Agid Y; Eggert K; Widner H; Ostergaard K; Holopainen A;
Eur Neurol; 2005; 53(4):197-202. PubMed ID: 15970632
[TBL] [Abstract][Full Text] [Related]
16. Optimizing levodopa therapy to treat wearing-off symptoms in Parkinson's disease: focus on levodopa/carbidopa/entacapone.
Reichmann H; Emre M
Expert Rev Neurother; 2012 Feb; 12(2):119-31. PubMed ID: 22288667
[TBL] [Abstract][Full Text] [Related]
17. The controversy concerning plasma homocysteine in Parkinson disease patients treated with levodopa alone or with entacapone: effects of vitamin status.
Zesiewicz TA; Wecker L; Sullivan KL; Merlin LR; Hauser RA
Clin Neuropharmacol; 2006; 29(3):106-11. PubMed ID: 16772808
[TBL] [Abstract][Full Text] [Related]
18. The influence of levodopa and the COMT inhibitor on serum vitamin B12 and folate levels in Parkinson's disease patients.
Triantafyllou NI; Kararizou E; Angelopoulos E; Tsounis S; Boufidou F; Evangelopoulos ME; Nikolaou C; Vassilopoulos D
Eur Neurol; 2007; 58(2):96-9. PubMed ID: 17565222
[TBL] [Abstract][Full Text] [Related]
19. Reversible encephalopathy and axonal neuropathy in Parkinson's disease during duodopa therapy.
Manca D; Cossu G; Murgia D; Molari A; Ferrigno P; Marcia E; Melis M
Mov Disord; 2009 Nov; 24(15):2293-4. PubMed ID: 19795477
[No Abstract] [Full Text] [Related]
20. Homocysteine in restless legs syndrome.
Bachmann CG; Guth N; Helmschmied K; Armstrong VW; Paulus W; Happe S
Sleep Med; 2008 May; 9(4):388-92. PubMed ID: 17900981
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
